Roughly 28 MM Americans live with Type-2 Diabetes, and this daily burden is compounded by very poor mediation compliance. 50% of T2D patients, frustrated with their results, stop taking their medication within 3 months.
Enter INVOKANA CarePath. This comprehensive Patient Support Program demonstrates that INVOKANA stands ready to back up its promise that if people who take – and keep taking – the brand can love their numbers (e.g., A1C blood sugar readings) again and again.
View all work from Johnson & Johnson - INVOKANA »